Visible-absorption spectroscopy as a biomarker to predict treatment response and prognosis of surgically resected esophageal cancer.
The application of optical absorption spectra in prognostic prediction has hardly been investigated. We developed and evaluated a novel two dimensional absorption spectrum measurement system (TDAS) for use in early diagnosis, evaluating response to chemoradiation, and making prognostic prediction. The absorption spectra of 120 sets of normal and tumor tissues from esophageal cancer patients were analyzed with TDAS ex-vivo. We demonstrated the cancerous tissue, the tissue from patients with a poor concurrent chemoradiotherapy (CCRT) response, and the tissue from patients with an early disease progression each had a readily identifiable common spectral signature. Principal component analysis (PCA) classified tissue spectra into distinct groups, demonstrating the feasibility of using absorption spectra in differentiating normal and tumor tissues, and in predicting CCRT response, poor survival and tumor recurrence (efficiencies of 75%, 100% and 85.7% respectively). Multivariate analysis revealed that patients identified as having poor-response, poor-survival and recurrence spectral signatures were correlated with increased risk of poor response to CCRT (P = 0.012), increased risk of death (P = 0.111) and increased risk of recurrence (P = 0.030) respectively. Our findings suggest that optical absorption microscopy has great potential to be a useful tool for pre-operative diagnosis and prognostic prediction of esophageal cancer.
Department of Surgery, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.
Pei-Wen
PW
Yang
Department of Physics and Center for Biomedical Technology, Chung Yuan Christian University, Taoyuan, Taiwan.
I-Jen
IJ
Hsu
Department of Physics and Center for Biomedical Technology, Chung Yuan Christian University, Taoyuan, Taiwan.
Chun-Wei
CW
Chang
Department of Physics and Center for Biomedical Technology, Chung Yuan Christian University, Taoyuan, Taiwan.
Yu-Chia
YC
Wang
Department of Surgery, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.
Ching-Yueh
CY
Hsieh
Department of Surgery, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.
Kuan-Hui
KH
Shih
Department of Surgery, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.
Li-Fan
LF
Wong
Department of Surgery, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.
Nai-Yu
NY
Shih
Graduate Institute of Pathology, National Taiwan University College of Medicine, Taipei, Taiwan.
Min-Shu
MS
Hsieh
Department of Mechanical Engineering, National United University, Miaoli, Taiwan.
Max Ti-Kuang
MT
Hou
Department of Surgery, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.
Jang-Ming
JM
Lee
D000230:Adenocarcinoma / Q000175:diagnosis / Q000601:surgery; D014408:Biomarkers, Tumor / Q000378:metabolism*; D059248:Chemoradiotherapy; D018572:Disease-Free Survival; D004938:Esophageal Neoplasms / Q000175:diagnosis* / Q000601:surgery*; D004947:Esophagus / Q000473:pathology / Q000601:surgery; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009364:Neoplasm Recurrence, Local / Q000473:pathology; D025341:Principal Component Analysis; D011379:Prognosis; D013057:Spectrum Analysis / Q000379:methods*; D016896:Treatment Outcome
D014408:Biomarkers, Tumor